STAAR Surgical (NASDAQ: STAA) reported Q4 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $22.06 million.

Fourth Quarter 2016 Overview

• Record Quarterly Net Sales of $22.1 Million Up 6% from the Prior Year Quarter
• Record Quarter for ICL Sales Up 11% and Units Up 10% from the Prior Year Quarter
• IOL Sales Flat and Units Up 5% from the Prior Year Quarter
• Gross Margin Improved to 71.7% of Sales from 70.3% of Sales in the Prior Year Quarter
• On-Going FDA Remediation Effort Finished the Quarter On-Track and On-Budget
• Fourth Quarter Breakeven per Share; Adjusted Net Income of $0.02 per Share
• Cash and Equivalents Ended the Quarter at $14.0 Million.

For earnings history and earnings-related data on STAAR Surgical (STAA) click here.